Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLKJD9)

Drug Name

9-(4-Hydroxybutyl)-N2-Phenylguanine Drug Info

Synonyms

9-(4-HYDROXYBUTYL)-N2-PHENYLGUANINE; HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 135415618
CAS Number: CAS 161363-19-5
TTD Drug ID: DMLKJD9

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Thymidine kinase 1 (TK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Penciclovir	DMOUMDV	Human immunodeficiency virus infection	1C62	Approved	[1]
DEOXYCYTIDINE	DMYE5LJ	Acute myeloid leukaemia	2A60	Approved	[2]
TK-DLI	DM26I8H	Graft-versus-host disease	4B24	Preregistration	[3]
FV-100	DMZARP1	Varicella zoster virus infection	1E91	Phase 3	[4]
Radiosensitizer gene therapy	DMN1ZEU	Pancreatic cancer	2C10	Phase 3	[5]
RP101	DMNIYSZ	Infectious disease	1A00-CA43.1	Phase 2/3	[6]
HQK-1004	DM3WX0K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
Rilapladib	DMB9861	Arteriosclerosis	BD40	Phase 1	[8]
Ad-OC-hsvTK/valacyclovir	DM9GLHO	Prostate cancer	2C82.0	Phase 1	[9]
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy	DMO8SGD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thymidine kinase 1 (TK1)	TTP3QRF	KITH_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
3	Company report (Takara Bio)
4	Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
5	Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
6	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
7	Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
8	Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
9	Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
10	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.